NASDAQ | ETF
The fund invests at least 80% of its total assets in the securities of the underlying index.
The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, Genomics & Biotechnology Companies), as defined by Solactive AG, the provider of the underlying index.
The fund is non-diversified.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| MRNA | Moderna Inc | Healthcare | Biotechnology | 8.05% |
| PRAX | Praxis Precision Medicines Inc | Healthcare | Biotechnology | 6.46% |
| ARWR | Arrowhead Pharmaceuticals Inc | Healthcare | Biotechnology | 6.19% |
| ILMN | Illumina Inc | Healthcare | Diagnostics & Research | 5.48% |
| GH | Guardant Health Inc | Healthcare | Diagnostics & Research | 5.06% |
| BMRN | Biomarin Pharmaceutical Inc | Healthcare | Biotechnology | 4.42% |
| NTRA | Natera Inc | Healthcare | Diagnostics & Research | 4.33% |
| VRTX | Vertex Pharmaceuticals Inc | Healthcare | Biotechnology | 4.24% |
| RNA | Atrium Therapeutics, Inc. Common Stock | Healthcare | Biotechnology | 3.75% |
| QGEN | Qiagen NV | Healthcare | Diagnostics & Research | 3.66% |
| BNTX | BioNTech SE | Healthcare | Biotechnology | 3.60% |
| TECH | Bio-Techne Corp | Healthcare | Biotechnology | 3.54% |
| QIA | QIAGEN NV | Healthcare | Diagnostics & Research | 3.35% |
| CRSP | Crispr Therapeutics AG | Healthcare | Biotechnology | 3.20% |
| BMY | Bristol-Myers Squibb Company | Healthcare | Drug Manufacturers - General | 2.84% |
| TWST | Twist Bioscience Corp | Healthcare | Diagnostics & Research | 2.82% |
| ALNY | Alnylam Pharmaceuticals Inc | Healthcare | Biotechnology | 2.80% |
| AZN | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 2.49% |
| GILD | Gilead Sciences Inc | Healthcare | Drug Manufacturers - General | 2.41% |
| VCYT | Veracyte Inc | Healthcare | Diagnostics & Research | 2.38% |